Glycosylation signature of plasma IgA of critically ill COVID-19 patients

Front Immunol. 2024 Oct 24:15:1439248. doi: 10.3389/fimmu.2024.1439248. eCollection 2024.

Abstract

Thromboembolic complications are common in severe COVID-19 and are thought to result from excessive neutrophil-extracellular-trap (NET)-driven immunothrombosis. Glycosylation plays a vital role in the efficiency of immunoglobulin A (IgA) effector functions, with significant implications for NET formation in infectious diseases. This study represents the first comprehensive analysis of plasma IgA glycosylation during severe SARS-CoV-2 or Influenza A infection, revealing lower sialylation and higher galactosylation of IgA1 O-glycans in acute respiratory distress syndrome (ARDS), regardless of the underlying cause of the disease. Importantly, N-glycans displayed an infection-specific pattern, with N47 of IgA2 showing diminished sialylation and bisection, and N340/N327 of IgA1/2 demonstrating lower fucosylation and antennarity along with higher non-complex glycans in COVID-19 compared to Influenza. Notably, COVID-19 IgA possessed strong ability to induce NET formation and its glycosylation patterns correlated with extracellular DNA levels in plasma of critically ill COVID-19 patients. Our data underscores the necessity of further research on the role of IgA glycosylation in the modulation of pathogen-specific immune responses in COVID-19 and other infectious diseases.

Keywords: ARDS; COVID-19; NETosis; glycosylation; immunoglobulin A.

MeSH terms

  • Adult
  • Aged
  • COVID-19* / blood
  • COVID-19* / immunology
  • Critical Illness*
  • Female
  • Glycosylation
  • Humans
  • Immunoglobulin A* / blood
  • Immunoglobulin A* / immunology
  • Influenza, Human / blood
  • Influenza, Human / immunology
  • Male
  • Middle Aged
  • Polysaccharides* / blood
  • Polysaccharides* / immunology
  • Respiratory Distress Syndrome / blood
  • Respiratory Distress Syndrome / immunology
  • SARS-CoV-2* / immunology

Substances

  • Immunoglobulin A
  • Polysaccharides

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by German Research Foundation (DFG; SFB/TR84 Project A2 to MWy, Project F11-259130777-SFB1177 to LS), German Center for Lung Research (82DZL005A1 to MWy), and Cardio-Pulmonary Institute (EXC2026, Project ID: 390649896 to LS and MWy). We acknowledge support from the European Union (European Research Council Synergy, GlycanSwitch, Project 101071386).